References
- Weycker D , MalinJ, EdelsbergJ, GlassA, GokhaleM, OsterGet al. Cost of neutropenic complications of chemotherapy. Ann Oncol.. 19(3), 454–460 (2007).
- Siegel RL , MillerKD, JemalA. Cancer statistics, 2018. CA Cancer J. Clin.68(1), 7–30 (2018).
- Sanli O , DobruchJ, KnowlesMAet al. Bladder cancer. Nat. Rev. Dis. Primers3, 17022 (2017).
- Mari A , CampiR, TelliniRet al. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. World J. Urol.36(2), 157–170 (2018).
- American Cancer Society . Survival rates for bladder cancer (2017). www.cancer.org/cancer/bladder-cancer/detection-diagnosis-staging/survival-rates.html
- Makhinova T , BarnerJC, RichardsKMet al. Asthma controller medication adherence, risk of exacerbation, and use of rescue agents among texas medicaid patients with persistent asthma. J. Manag. Care Spec. Pharm.21(12), 1124–1132 (2015).
- Oing C , RinkM, OechsleK, SeidelC, Von AmsbergG, BokemeyerC. Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond – a comprehensive review of the current literature. J. Urol.195(2), 254–263 (2016).
- Massard C , GordonMS, SharmaSet al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol.34(26), 3119–3125 (2016).
- Ning YM , SuzmanD, MaherVEet al. FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy. Oncologist22(6), 743–749 (2017).
- Sharma P , RetzM, Siefker-RadtkeAet al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, Phase II trial. Lancet Oncol.18(3), 312–322 (2017).
- Apolo AB , InfanteJR, BalmanoukianAet al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, Phase Ib study. J. Clin. Oncol.35(19), 2117–2124 (2017).
- Bellmunt J , DeWit R, VaughnDJet al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med.376(11), 1015–1026 (2017).
- Balar AV , CastellanoD, O’DonnellPHet al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, Phase 2 study. Lancet Oncol.18(11), 1483–1492 (2017).
- Balar AV , GalskyMD, RosenbergJEet al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet389(10064), 67–76 (2017).
- Genentech . TECENTRIQ® (atezolizumab): highlights of prescribing information (2019). www.gene.com/download/pdf/tecentriq_prescribing.pdf
- Merck & Co. KEYTRUDA® (pembrolizumab): highlights of prescribing information (2019). www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
- Aly A , JohnsonC, YangS, BottemanMF, RaoS, HussainA. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma. J. Med. Econ.22(7), 662–670 (2019).
- Nishijima TF , ShacharSS, NyropKA, MussHB. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist22(4), 470–479 (2017).
- Wong W , YimYM, KimAet al. Assessment of costs associated with adverse events in patients with cancer. PLoS ONE13(4), e0196007 (2018).
- Hurvitz S , GuerinA, BrammerMet al. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist19(9), 901–908 (2014).
- Lang K , MarciniakMD, FariesDet al. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States. Value Health12(4), 481–488 (2009).
- US FDA . Prescribing information – IMFINZI® (durvalumab) (2019). www.accessdata.fda.gov/drugsatfda_docs/label/2019/761069s013lbl.pdf
- US FDA . Prescribing information – OPDIVO (nivolumab) (2019). www.accessdata.fda.gov/drugsatfda_docs/label/2015/125527s000lbl.pdf
- US FDA . Prescribing information – TECENTRIQ® (atezolizumab) (2017). www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s014lbl.pdf
- US FDA . Prescribing information – BAVENCIO® (Avelumab) (2019). www.accessdata.fda.gov/drugsatfda_docs/label/2019/761049s006lbl.pdf
- US FDA . Prescribing information – KEYTRUDA® (pembrolizumab) (2019). www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s055s056lbl.pdf
- Chu JN , ChoiJG, OstvarSet al. Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: a single center experience. J. Clin. Oncol.36(Suppl. 15), 3060 (2018).
- American Cancer Society . Key statistics for bladder cancer (2019). www.cancer.org/cancer/bladder-cancer/about/key-statistics.html